A multicenter, phase II study of bortezomib and dexamethasone as induction treatment followed by high dose melphalan (HDM) and autologous stem cell transplantation (SCT) in patients with de novo amyloid light chain (AL) amyloidosis. - HOVON 104 AL amyloidosis

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2011
This article has no abstract
Epistemonikos ID: 0369d19466ab5b5e09925413210046ba49346876
First added on: Apr 17, 2025